Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa

Journal of Infection

Volumn 60, Issue 6, 2010, Pages 496-498

  Jarvis, Joseph N ^a,b,c   Meintjes, Graeme ^a,b   Harrison, Thomas S ^b  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; GAMMA INTERFERON;

ANTIGEN DETECTION; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; RELAPSE; SOUTH AFRICA; TREATMENT DURATION; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MENINGITIS, CRYPTOCOCCAL; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 77953324038     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.007     Document Type: Letter

References (11)

1. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009 Feb 20, 23(4):525-530.
2. Jarvis J.N., Boulle A., Loyse A., Bicanic T., Rebe K., Williams A., et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 2009, 23:1181-1185.
3. Lawn S., Harries A., Anglaret X., Myer L., Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008 Oct 1, 22(15):1897-1908.
4. Lortholary O., Poizat G., Zeller V., Neuville S., Boibieux A., Alvarez M., et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006 Nov 14, 20(17):2183-2191.
5. Bicanic T., Meintjes G., Wood R., Hayes M., Rebe K., Bekker L.G., et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007 July 1, 45(1):76-80.
6. Bisson G.P., Nthobatsong R., Thakur R., Lesetedi G., Vinekar K., Tebas P., et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in botswana. J Acquir Immune Defic Syndr Sep 2, 2008.
7. Jarvis J.N., Meintjes G., Williams A., Brown Y., Crede T., Harrison T.S. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010 Mar 15, 10(1):67.
8. Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison T. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, in press.
9. Bicanic T., Muzoora C., Brouwer A.E., Meintjes G., Longley N., Taseera K., et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009 Sep 1, 49(5):702-709.
10. French M.A., Price P., Stone S.F. Immune restoration disease after antiretroviral therapy. AIDS 2004 Aug 20, 18(12):1615-1627.
11. Jarvis J.N., Lawn S.D., Vogt M., Bangani N., Wood R., Harrison T.S. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009 April, 48(7):856-862.